10x Genomics Debt/Equity Ratio 2018-2025 | TXG

10x Genomics debt/equity ratio from 2018 to 2025. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

10x Genomics Debt/Equity Ratio 2018-2025 | TXG

10x Genomics debt/equity ratio from 2018 to 2025. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Veeva Systems (VEEV)$35.1B
Tempus AI (TEM)$7B
Hims & Hers Health (HIMS)$6B
Inspire Medical Systems (INSP)$4.5B
IRhythm Technologies (IRTC)$3.2B
Privia Health (PRVA)$2.9B
Schrodinger (SDGR)$1.9B
Clover Health Investments (CLOV)$1.8B
Enovis (ENOV)$1.8B
Omnicell (OMCL)$1.4B
Phreesia (PHR)$1.4B
Azenta (AZTA)$1.2B
Butterfly Network (BFLY)$568M
Fulgent Genetics (FLGT)$551M
Talkspace (TALK)$450M
Veradigm (MDRX)$449M
Standard BioTools (LAB)$440M
TruBridge (TBRG)$363M
Claritev (CTEV)$325M
Health Catalyst (HCAT)$270M
Nyxoah SA (NYXH)$206M
SOPHiA GENETICS SA (SOPH)$189M
Pulmonx (LUNG)$182M
American Well (AMWL)$109M
EUDA Health Holdings (EUDA)$100M
Retrieve Medical Holdings (RMHI)$82M
MDxHealth SA (MDXH)$76M
P3 Health Partners (PIII)$66M
111 (YI)$64M
CareCloud (CCLD)$60M